Celcuity CELC
NASDAQ CELC
$95.70 -0.73 (-0.76%)
As of: Sep 4, 2026 · 3:59 PM EDT

Celcuity (CELC) Cash from Financing Activities (2016 - 2025)

Celcuity's (CELC) quarterly Cash from Financing Activities came in at $24.4 million in Q4 2025, up 19770.73% YoY from N/an in Q4 2024, and down 92.6% on a QoQ basis from $330.3 million in Q3 2025.

Analysis

Celcuity (CELC) Cash from Financing Activities (2016 - 2025) Analysis & Trends

Celcuity (CELC) has 10 years of Cash from Financing Activities data on file, last reported at $24.4 million in Q4 2025.

  • Quarterly Cash from Financing Activities rose 19770.73% year-over-year to $24.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $360.6 million (up 160.54% YoY) and the FY2025 annual result came in at $360.6 million, up 160.54% from the prior year.
  • Cash from Financing Activities slipped to $24.4 million in Q4 2025, from $330.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $330.3 million in Q3 2025 to a low of -$108166.0 in Q3 2022.
  • A 5-year average of $38.9 million and a median of $3.2 million in 2024 frame the typical range for Cash from Financing Activities.
  • Annual changes were most pronounced in 2021 — Cash from Financing Activities surged 1797799.65% — and 2022, when it plunged 100.51%.
  • Tracing CELC's Cash from Financing Activities over 5 years: stood at $53510.0 in 2021, then jumped by 225188.94% to $120.6 million in 2022, then slumped by 46.37% to $64.7 million in 2023, then slumped by 99.81% to $123000.0 in 2024, then surged by 19770.73% to $24.4 million in 2025.
  • The last three Cash from Financing Activities figures came in at $24.4 million (Q4 2025), $330.3 million (Q3 2025), and $232000.0 (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 14.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 2.42 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -6.05 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 36.24 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -273.15 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 27.18 Mn
10 Celcuity 5.25 Bn 5.25 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 24.44 Mn
Sep 30, 2025 330.33 Mn
Jun 30, 2025 232,000.00
Mar 31, 2025 5.55 Mn
Dec 31, 2024 123,000.00
Sep 30, 2024 803,000.00
Jun 30, 2024 123.38 Mn
Mar 31, 2024 14.08 Mn
Dec 31, 2023 64.66 Mn
Sep 30, 2023 15,244.00
Jun 30, 2023 171,547.00
Mar 31, 2023 67,948.00
Dec 31, 2022 120.55 Mn
Sep 30, 2022 -108,166.00
Jun 30, 2022 -72,516.00
Mar 31, 2022 -46,288.00
Dec 31, 2021 53,510.00
Sep 30, 2021 52.79 Mn
Jun 30, 2021 14.35 Mn
Mar 31, 2021 25.85 Mn